Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-Dense Paclitaxel and Carboplatin in Ovarian Cancer
NCT00750386Phase 2Completed
- Sponsor
- Hellenic Oncology Research Group
- Start
- Jan 2008
- Primary completion
- Mar 2011
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of paclitaxel and carboplatin in ovarian cancer, sponsored by Hellenic Oncology Research Group. Primary endpoints: Maximum Tolerated Dose at Cycle 1 and Objective Response Rate at Cycle 6. Started Jan 2008; status: completed.
02
Drugs
paclitaxelcarboplatin
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT00750386.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00750386.